PMC:7228307 / 51771-52065 JSONTXT

{"project":"LitCovid-PubTator","denotations":[{"id":"1031","span":{"begin":186,"end":191},"obj":"Gene"},{"id":"1032","span":{"begin":256,"end":260},"obj":"Gene"},{"id":"1033","span":{"begin":84,"end":88},"obj":"Gene"},{"id":"1034","span":{"begin":40,"end":55},"obj":"Chemical"},{"id":"1035","span":{"begin":159,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A1031","pred":"tao:has_database_id","subj":"1031","obj":"Gene:29126"},{"id":"A1032","pred":"tao:has_database_id","subj":"1032","obj":"Gene:2213"},{"id":"A1033","pred":"tao:has_database_id","subj":"1033","obj":"Gene:2213"},{"id":"A1035","pred":"tao:has_database_id","subj":"1035","obj":"MESH:C000594389"}],"namespaces":[{"prefix":"Tax","uri":"https://www.ncbi.nlm.nih.gov/taxonomy/"},{"prefix":"MESH","uri":"https://id.nlm.nih.gov/mesh/"},{"prefix":"Gene","uri":"https://www.ncbi.nlm.nih.gov/gene/"},{"prefix":"CVCL","uri":"https://web.expasy.org/cellosaurus/CVCL_"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-PD-CLO","denotations":[{"id":"T873","span":{"begin":84,"end":86},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T874","span":{"begin":126,"end":128},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T875","span":{"begin":142,"end":144},"obj":"http://purl.obolibrary.org/obo/CLO_0001313"},{"id":"T876","span":{"begin":155,"end":158},"obj":"http://purl.obolibrary.org/obo/CLO_0054060"},{"id":"T877","span":{"begin":186,"end":191},"obj":"http://purl.obolibrary.org/obo/CLO_0008407"},{"id":"T878","span":{"begin":256,"end":258},"obj":"http://purl.obolibrary.org/obo/CLO_0052676"},{"id":"T879","span":{"begin":281,"end":291},"obj":"http://purl.obolibrary.org/obo/CLO_0001658"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-PD-CHEBI","denotations":[{"id":"T98482","span":{"begin":186,"end":188},"obj":"Chemical"},{"id":"T9506","span":{"begin":203,"end":212},"obj":"Chemical"}],"attributes":[{"id":"A56840","pred":"chebi_id","subj":"T98482","obj":"http://purl.obolibrary.org/obo/CHEBI_74756"},{"id":"A59787","pred":"chebi_id","subj":"T9506","obj":"http://purl.obolibrary.org/obo/CHEBI_35222"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sample-Pubtator","denotations":[{"id":"1031","span":{"begin":186,"end":191},"obj":"Gene"},{"id":"1032","span":{"begin":256,"end":260},"obj":"Gene"},{"id":"1033","span":{"begin":84,"end":88},"obj":"Gene"},{"id":"1034","span":{"begin":40,"end":55},"obj":"Chemical"},{"id":"1035","span":{"begin":159,"end":171},"obj":"Chemical"}],"attributes":[{"id":"A1031","pred":"pubann:denotes","subj":"1031","obj":"Gene:29126"},{"id":"A1032","pred":"pubann:denotes","subj":"1032","obj":"Gene:2213"},{"id":"A1035","pred":"pubann:denotes","subj":"1035","obj":"MESH:C000594389"},{"id":"A1033","pred":"pubann:denotes","subj":"1033","obj":"Gene:2213"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sample-sentences","denotations":[{"id":"T295","span":{"begin":0,"end":294},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sample-UniProt","denotations":[{"id":"T695","span":{"begin":186,"end":191},"obj":"Protein"}],"attributes":[{"id":"A695","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q9NZQ7"},{"id":"A696","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q9NUZ5"},{"id":"A697","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q9EP73"},{"id":"A698","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q6WEX4"},{"id":"A699","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q66RK1"},{"id":"A700","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q2V8D5"},{"id":"A701","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/Q14CJ2"},{"id":"A702","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/B4DU27"},{"id":"A703","pred":"uniprot_id","subj":"T695","obj":"https://www.uniprot.org/uniprot/B2RBA2"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sample-PD-GO-BP-0","denotations":[{"id":"T121","span":{"begin":270,"end":291},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sample-GO-BP","denotations":[{"id":"T121","span":{"begin":270,"end":291},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-PD-GO-BP","denotations":[{"id":"T121","span":{"begin":270,"end":291},"obj":"http://purl.obolibrary.org/obo/GO_0006956"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}

{"project":"LitCovid-sentences","denotations":[{"id":"T295","span":{"begin":0,"end":294},"obj":"Sentence"}],"namespaces":[{"prefix":"_base","uri":"http://pubannotation.org/ontology/tao.owl#"}],"text":"The complete removal of the heavy‐chain N‐linked glycan is well known to ablate all FcγR binding by dramatically altering the Fc conformation.36, 67, 101, 102 Atezolizumab, an IgG1 anti‐PD‐L1 checkpoint inhibitor mAb, utilizes this strategy and eliminates FcγR and also complement activation.13"}